BioNTech SE (BNTX) Accounts Payables (2018 - 2025)

BioNTech SE has reported Accounts Payables for 8 years, with the latest figure at $622.6 million in Q4 2025.

• Quarterly Accounts Payables rose 36.55% year-over-year to $622.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $622.6 million (up 36.55% YoY) and the FY2025 annual result came in at $604.3 million, up 32.54% from the prior year.
• Accounts Payables grew to $622.6 million in Q4 2025 per BNTX's latest filing, from $467.4 million in the prior quarter.
• Over five years, Accounts Payables peaked at $949.3 million in Q2 2024 and troughed at $32.1 million in Q1 2023.
• A 5-year average of $381.5 million and a median of $317.6 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables tumbled 76.88% in 2023, then jumped 911.45% in 2024.
• Over 5 years, Accounts Payables stood at $183.0 million in 2021, then grew by 13.77% to $208.2 million in 2022, then jumped by 82.91% to $380.9 million in 2023, then climbed by 19.71% to $456.0 million in 2024, then soared by 36.55% to $622.6 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $622.6 million, $467.4 million, and $570.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.